| |
 |
 |
 |
 |
 |
GlycoFi owns or controls over 60 issued and pending
patents in the U.S. and abroad relating to glycosylation
engineering and the production of human glycoproteins
with proper glycosylation in yeast and fungi. Additionally,
we have in-licensed complementary protein expression
technology. GlycoFi’s strategy is to secure
global intellectual property protection for our
protein expression technology, as well as specific
glycan structure-protein activity relationships,
with the ability to freely license our intellectual
property rights and know-how to others.
|
 |
|
 |
|
|
|
